Related Experiment Videos
Urinary hesitancy and retention caused by ziprasidone.
Dimitris Xomalis1, Vasilis P Bozikas, George Garyfallos
1Second Department of Psychiatry, Aristotle University of Thessaloniki, Greece.
International Clinical Psychopharmacology
|December 1, 2005
Summary
Ziprasidone, an antipsychotic, can cause urinary retention in schizophrenia patients. Discontinuing the medication resolved the urinary hesitancy and retention symptoms.
Area of Science:
- Psychiatry
- Urology
- Pharmacology
Background:
- Schizophrenia is a chronic mental disorder often treated with antipsychotic medications.
- Ziprasidone is a second-generation antipsychotic used for managing schizophrenia.
- Urinary dysfunction is a potential adverse effect of some psychotropic medications.
Observation:
- A patient with schizophrenia developed progressive urinary hesitancy and retention.
- These urinary symptoms emerged after 6 months of continuous ziprasidone treatment.
- No other medications were administered concurrently.
Findings:
- Ziprasidone treatment was directly linked to the onset of urinary hesitancy and retention.
- Immediate resolution of micturition difficulties occurred upon ziprasidone discontinuation.
- This suggests a causal relationship between ziprasidone and the observed urinary adverse effects.
Implications:
- Clinicians should monitor for urinary symptoms in schizophrenia patients treated with ziprasidone.
- Early recognition and discontinuation of ziprasidone may prevent severe urinary retention.
- Further research is warranted to elucidate the mechanism of ziprasidone-induced urinary retention.